Biomerica, Inc. announced that its Fortel Kidney Disease (Microalbumin) Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This key regulatory milestone enables Biomerica to offer its innovative test across the UAE, a region facing a high burden of chronic kidney disease (CKD). The Fortel Kidney Disease Test is a rapid, easy-to-use diagnostic tool that provides accurate results in 10 minutes using a urine sample.
By detecting low levels of microalbumin in urine, a critical early marker, the test can enable the early detection of kidney disease. Individuals with diabetes, hypertension, obesity, and those over 65 are at significantly increased risk for developing CKD. In the UAE, over 12% of adults live with diabetes, and 29% to 35% of the population has hypertension, both major risk factors for CKD.
Early detection of CKD allows for timely intervention that can slow or prevent progression to end-stage renal disease, reducing morbidity, mortality, and economic burden. This approval builds on Biomerica’s growing presence in the Middle East, following the regional success of its EZ Detect Colon Disease Test. CEO Zack Irani stated that the test addresses a critical need in preventative healthcare by allowing possible detection of kidney disease before symptoms appear.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.